Not known Facts About YX-2-107
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review To judge multiple intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Major trial aims were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, wh